Do GLP-1 drugs actually reduce cravings for alcohol and addictive foods?
Yes — and the strongest evidence comes from a 2025 phase 2 randomized controlled trial of semaglutide in 48 adults with alcohol use disorder. Participants on semaglutide reported a 39% greater reduction in weekly alcohol craving compared to placebo, and they drank 41% fewer drinks per drinking day [1]. In a lab setting, they also consumed less alcohol and had lower peak breath alcohol levels [1]. These effects are not just about alcohol: the same trial found that semaglutide also reduced cigarette smoking in a subgroup of smokers [1], suggesting a broad effect on addictive behaviors.
The mechanism is neurobiological. GLP-1 receptors are located in brain reward regions like the nucleus accumbens, where they dampen dopamine release triggered by drugs and highly palatable foods [3]. Preclinical studies show that GLP-1 receptor agonists reduce the rewarding effects of alcohol, nicotine, cocaine, and opioids, and also reduce cue-induced relapse in animal models [3]. This means the same drug can simultaneously curb cravings for alcohol, nicotine, and hyper-palatable foods — a unique advantage over existing addiction medications that target only one substance [3].
However, not all GLP-1 drugs have shown consistent results. A 26-week trial of an older GLP-1 drug (exenatide) failed to reduce heavy drinking days overall, though it did help in patients who also had obesity [3]. This suggests that newer, more potent drugs like semaglutide may be more effective, and that the benefits may be strongest in people with both addiction and metabolic issues [2][3].
What happens to cravings when you stop GLP-1 drugs — does weight rebound bring them back?
Weight rebound after stopping GLP-1 drugs is well-documented. A 2026 study found that people who switched from injectable GLP-1s (tirzepatide or semaglutide) to a daily oral GLP-1 pill maintained only 75-79% of their earlier weight loss — meaning they regained about 21-25% of the weight they had lost [4]. This rebound is not a sign of weak willpower; it reflects the drug's removal from the brain's reward circuitry [5].
The neurobiological mechanisms that reduce cravings during treatment can reverse after discontinuation. During GLP-1 use, the drugs lower the motivational value of highly palatable foods by modulating mesolimbic dopamine signaling and glutamatergic pathways [5]. When the drug is stopped, food stimuli can become more prominent again, leading to a recurrence of food cravings and overeating [5]. Persistent low-grade inflammation and heightened stress responses may further amplify stimulus-driven eating and weaken inhibitory control [5].
Critically, no published study has directly measured whether weight rebound after GLP-1 cessation causes a return of alcohol cravings. The 2025 semaglutide trial lasted only 9 weeks and did not follow participants after discontinuation [1]. Experts note that this is a major gap: we do not know whether drinking reductions or other clinical benefits are sustained without ongoing medication [2]. The same concern applies to addictive foods — the neurobiological framework predicts a return of cravings, but dedicated clinical trials are needed [5].
Can the benefits be maintained — or is this a lifelong medication?
Current evidence suggests that GLP-1 drugs may need to be considered a chronic therapy for both weight management and addiction. In metabolic populations, discontinuation typically leads to substantial weight regain, and there is no established guidance on tapering or stopping these drugs in the context of addiction [2]. The 2026 review on weight rebound explicitly calls for maintenance approaches that combine pharmacological, behavioral, and lifestyle strategies to sustain long-term results [5].
The good news is that the same drug can address both weight and addiction simultaneously, which may improve treatment adherence. People with alcohol use disorder often have metabolic comorbidities, and the prospect of weight management can serve as a motivator to stay on the medication [2]. However, adherence rates from metabolic populations may not generalize to addiction cohorts, who face different motivations and side-effect tolerances [2].
For now, the most practical takeaway is this: GLP-1 drugs can powerfully reduce cravings for alcohol and addictive foods while you are taking them, but stopping the medication likely reverses those benefits. If you are considering these drugs for addiction, plan for long-term use and combine them with behavioral support to protect against rebound [2][5].
About These Sources
This answer is built on 5 peer-reviewed studies — published from 2024 to 2026, 5 from 2024 or later, 4 in Q1 journals, collectively cited 135 times — selected as the most relevant from 5 studies that passed quality screening, drawn from 60 papers retrieved from a database of over 500 million.
Sources used in this answer
Once-Weekly Semaglutide in Adults With Alcohol Use Disorder
In a 9-week phase 2 randomized controlled trial of 48 adults with alcohol use disorder, semaglutide reduced alcohol self-administration in the lab, cut weekly alcohol craving by 39%, and reduced drinks per drinking day by 41% compared to placebo; it also reduced cigarette smoking in a subgroup of smokers.
Glucagon‐like peptide‐1 receptor agonists in alcohol use disorder: Multi‐system effects, early clinical promise and uncertain long‐term use
This 2026 review argues that GLP-1 receptor agonists show early promise for alcohol use disorder by modulating both central reward pathways and peripheral metabolism, but critical questions remain about long-term efficacy, optimal dosing, and whether benefits persist after discontinuation.
GLP‐1R agonist medications for addiction treatment
This 2024 review summarizes preclinical and clinical evidence that GLP-1 receptor agonists reduce the rewarding effects of alcohol, nicotine, cocaine, and opioids by dampening dopamine release in the nucleus accumbens; it notes that an older GLP-1 drug (exenatide) failed to reduce heavy drinking in a 26-week trial except in patients with obesity.
GLP-1: Daily pill reduces weight rebound after stopping injections, study suggests.
A 2026 study of 376 participants found that switching from injectable GLP-1s (tirzepatide or semaglutide) to a daily oral GLP-1 pill helped people maintain 75-79% of their earlier weight loss, meaning they regained about 21-25% of lost weight.
Mechanisms Underlying Weight Regain After GLP-1RA Treatment: A Neurobiological Perspective
This 2026 review explains that weight rebound after stopping GLP-1 drugs is driven by the return of food stimulus-driven eating as the drug's effects on mesolimbic reward circuitry fade, and recommends combining pharmacological, behavioral, and lifestyle strategies for long-term maintenance.